 |
 |
| |
Statutory
presentation
9 months to
31 Dec 1997
(restated)
£m
|
|
Unaudited
Pro forma
12 months to
31 Dec 1997
(restated)
£m
|
|
12
months to
31 Dec 1998
(restated)
£m
|
|
12
months to
31 Dec 1999
(restated)
£m
|
|
12
months to
31 Dec 2000
(restated)
£m
|
|
12
months to
31 Dec 2001
£m
|
|
|
| Key data |
|
|
|
|
|
|
|
|
|
|
|
|
| Sales |
589.7 |
|
1,372.9 |
|
1,388.9 |
|
1,374.6 |
|
1,377.6 |
|
1,602.5 |
|
| – continuing operations |
505.6 |
|
1,081.9 |
|
1,113.7 |
|
1,271.0 |
|
1,377.6 |
|
1,602.5 |
|
| – discontinued operations |
84.1 |
|
291.0 |
|
275.2 |
|
103.6 |
|
- |
|
- |
|
 |
| Amersham Health |
46.4 |
|
140.2 |
|
161.0 |
|
178.1 |
|
194.6 |
|
240.9 |
|
| Amersham Biosciences |
36.9 |
|
55.2 |
|
70.5 |
|
81.6 |
|
63.3 |
|
72.4 |
|
| Corporate |
(8.2 |
) |
(15.3 |
) |
(9.9 |
) |
(9.7 |
) |
(16.7 |
) |
(20.8 |
) |
|
| Operating profit of continuing operations before exceptional
items and goodwill amortisation |
75.1 |
|
180.1 |
|
221.6 |
|
250.0 |
|
241.2 |
|
292.5 |
|
| Discontinued operations |
3.4 |
|
42.7 |
|
37.7 |
|
10.3 |
|
- |
|
- |
|
|
| Total operating profit before exceptional items and goodwill
amortisation |
78.5 |
|
222.8 |
|
259.3 |
|
260.3 |
|
241.2 |
|
292.5 |
|
| Interest |
(8.3 |
) |
(30.1 |
) |
(33.3 |
) |
(27.1 |
) |
(10.0 |
) |
(8.7 |
) |
| Amounts written off investments |
- |
|
- |
|
- |
|
- |
|
- |
|
(4.4 |
) |
|
| Profit before tax and before exceptional items and goodwill
amortisation |
70.2 |
|
192.7 |
|
226.0 |
|
233.2 |
|
231.2 |
|
279.4 |
|
| Exceptional items |
(83.7 |
) |
- |
|
(35.1 |
) |
(55.2 |
) |
(27.0 |
) |
46.6 |
|
| Goodwill amortisation |
- |
|
- |
|
(2.4 |
) |
(8.9 |
) |
(10.7 |
) |
(11.7 |
) |
|
| Profit/(loss) before taxation after exceptional items and
goodwill amortisation |
(13.5 |
) |
192.7 |
|
188.5 |
|
169.1 |
|
193.5 |
|
314.3 |
|
|
| Profit/(loss) attributable to shareholders |
(22.9 |
) |
106.9 |
|
102.5 |
|
91.5 |
|
110.8 |
|
214.8 |
|
|
| Employment of shareholders’ funds |
|
|
|
|
|
|
|
|
|
|
|
|
| Fixed assets |
638.6 |
|
n/a |
|
751.2 |
|
677.5 |
|
776.7 |
|
787.9 |
|
| Net current assets |
263.7 |
|
n/a |
|
398.4 |
|
360.0 |
|
266.2 |
|
241.2 |
|
| Non-current liabilities (incl. deferred income) |
(495.2 |
) |
n/a |
|
(671.9 |
) |
(412.9 |
) |
(373.7 |
) |
(158.0 |
) |
| Provisions |
(220.4 |
) |
n/a |
|
(233.2 |
) |
(215.4 |
) |
(202.9 |
) |
(220.0 |
) |
|
| Net assets |
186.7 |
|
n/a |
|
244.5 |
|
409.2 |
|
466.3 |
|
651.1 |
|
|
| Shareholders’ funds |
150.5 |
|
n/a |
|
199.2 |
|
351.4 |
|
408.4 |
|
591.9 |
|
| Minority interests |
36.2 |
|
n/a |
|
45.3 |
|
57.8 |
|
57.9 |
|
59.2 |
|
|
| |
186.7 |
|
n/a |
|
244.5 |
|
409.2 |
|
466.3 |
|
651.1 |
|
|
| Net debt |
397.3 |
|
n/a |
|
523.8 |
|
298.9 |
|
323.5 |
|
25.4 |
|
|
| Share statistics |
|
|
|
|
|
|
|
|
|
|
|
|
| Earnings/(loss) per share |
|
|
|
|
|
|
|
|
|
|
|
|
| – basic |
(5.6 |
p) |
17.1 |
p |
16.4 |
p |
14.5 |
p |
17.6 |
p |
33.9 |
p |
– before exceptional items and
goodwill amortisation |
10.5 |
p |
17.1 |
p |
19.5 |
p |
21.1 |
p |
22.5 |
p |
27.2 |
p |
| Dividends per share |
3.4 |
p |
n/a |
|
5.3 |
p |
5.85 |
p |
6.4 |
p |
7.1 |
p |
|
Figures for periods ending 31 December 1997 and 31 December 1998
have been restated following the implementation of FRS 12. Sales
have been restated to reclassify Industrial Quality & Safety Assurance
and Nycomed Pharma as discontinued operations.
Earnings/(loss) per share for periods prior to 31 December 1998
have been restated for the effects of the share split and bonus
issue, which took place in 1998.
Figures for periods ending 31 December 1997, 1998, 1999 and 2000
have been restated following the introduction of FRS 18, as explained
in note 36 to the financial statements.
|
